Scott Freeman

MindMed expects to reach big milestones in 2024

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) announced its financial results for the year ended December 31, 2023, and provided a business update....

MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD / NEO: MMED), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...

MindMed Publishes Report by FDA Experts: Is FCM’s Takeover Attempt Over?

Earlier this month, we covered news of a group of activist investors (Freeman Capital Management) attempting to take control of MindMed’s board of directors. Today,...

MindMed Publishes Report Supporting Its Position On LSD Study Strategy

The battle over the board of psychedelic company Mind Medicine (NASDAQ: MNMD) continues with the latest volley being shot by the current company roster. MineMed ...

MindMed Addresses Board Coup, Says It Has Two-Year Cash Runway

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) (NEO: MMED) reported a net loss of $24.8 million for the first quarter ended March 31, compared with $18.5...

MindMed Drama: Freemans Attempt Board of Directors Takeover

The drama continues at MindMed. The (former?) fan-favorite has had a rough run, facing an industry-wide drop in share price while dealing with a string...

VIDEO: The MindMed Chronicles: What’s the Latest?

The following is a continuation of all our recent MindMed coverage. Last week, we published the first conversation with Jake Freeman. Click here to watch...

The MindMed Chronicles: Live Q&A with Jake Freeman of Freeman Capital (Part 3)

The following is a continuation of all our recent MindMed coverage. Last week, we published the first conversation with Jake Freeman. Click here to watch...

MindMed Mess Results in Stock Price Roller Coaster

It’s common knowledge that new businesses in emerging industries face significant obstacles. That’s never been truer than for startup psychedelics companies working with novel formulations...

The MindMed Chronicles: An Interview With Robert Barrow, the CEO of MindMed

The following is a continuation of all our recent MindMed coverage. Over the past few weeks, we published a few conversations with Jake Freeman. Click...

The MindMed Chronicles: Part 2 of the Interview with Jake Freeman of Freeman Capital

The following is a continuation of all our recent MindMed coverage. Last week, we published the first conversation with Jake Freeman. Click here to watch...

The MindMed Chronicles: A Conversation with Jake Freeman of Freeman Capital

The following is a continuation of all our recent MindMed coverage. It all began with a two-part interview with Dr. Scott Freeman last month. Click...

MindMed Raises $30 Million, Stock Plummets

Mind Medicine Inc. (“MindMed”) (NASDAQ: MNMD) (NEO: MMED) has priced its underwritten public offering of 7,058,823 common shares at $4.25. The shares come with warrants...

The MindMed Chronicles: New Shelf Offering on September 27, 2022

The following is a continuation of all our recent MindMed coverage. It all began with a two-part interview with Dr. Scott Freeman last month. Click...

MindMed Faces Tough IP Questions (and Publishes Positive Trial Results)

MindMed’s been in the news as of late. Two weeks ago Mindmed stock shot up over 60%, apparently due to meme-stock star Jake Freeman amassing...

Psychedelic Sector News – Weekly Extractions: September 6, 2022

In this edition of Weekly Extractions, host Adam Tubero discusses the latest events and happenings surrounding the hottest and most talked about psychedelics company right...

Psychedelic Sector News – Weekly Extractions: August 24, 2022

In this special edition of Weekly Extractions, Adam reviews recent events surrounding Bright Minds ($DRUG), Mydecine ($MYCO), and MindMed ($MNMD). Extraction #1: What’s Going On...

The Freeman Chronicles: An Interview with the Former CMO of MindMed (Part 2 of 2)

The following is part two of a two-part interview with Dr. Scott Freeman. Click here to watch part 1 of the interview. Revisiting “The Letter”...

The Freeman Chronicles: An Interview with the Former CMO of MindMed (Part 1 of 2)

Last week, an investor group made up of a few of the original co-founders of Mind Medicine ($MNMD) issued a letter to the company’s Board...

MindMed Co-Founder Dr. Scott Freeman Proposes Value Enhancement Plan

Today, FCM MM HOLDINGS, LLC announced that it has sent a letter to the Board of Directors of Mind Medicine Inc. (NASDAQ: MNMD) calling on...

MindMed

Co-Founder, Chief Medical Officer

Last updated: Jun 26, 2020

Request Deletion